TrialThe Journal of infectious diseases2024

Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial.

Xavier Sáez-Llorens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.